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Abstract
Background: To assess the outcome of neoadjuvant chemohormonal therapy comprising complete androgen
blockade followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in
Japanese patients with a high risk of localized prostate cancer (PCa).
Methods: Complete androgen blockade followed by 6 cycles of docetaxel (30 mg/m
2) with estramustine
phosphate (560 mg) were given to 18 PCa patients before radical prostatectomy. Subsequently, the clinical and
pathological outcomes were analyzed.
Results: No patients had severe adverse events during chemohormonal therapy, and hence they were treated
with radical prostatectomy. Two patients (11.1%) achieved pathological complete response. Surgical margins were
negative in all patients. At a median follow-up of 18 months, 14 patients (77.8%) were disease-free without PSA
recurrence. All 4 patients with PSA recurrence had pathologic T3b or T4 disease and 3 of these 4 patients had
pathologic N1 disease.
Conclusion: We found that neoadjuvant chemohormonal therapy with complete androgen blockade followed by
treatment with docetaxel and estramustine phosphate before radical prostatectomy was safe, feasible, and
associated with favorable pathological outcomes in patients with a high risk of localized PCa.
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Prostate cancer (PCa) is currently the most common
malignancy in men, and the second leading cause of can-
cer-related death in Western populations [1]. In Japan,
morbidity and mortality due to PCa have been increasing.
This increase may be due to changes in dietary habits,
increased screening for PCa, and an expanding elderly
population. Due to recent advances in surgical procedures,
the operative outcomes have been reported to improve
[2]. However, men with high-risk localized PCa [as defined
by the parameters including serum prostate-specific anti-
gen (PSA) levels, clinical stage, and histological grade]
have a significantly higher possibility of biochemical
relapse than the control groups [3,4]. To improve the out-
come of local therapy, several groups conducted neoadju-
vant hormonal therapy before radical prostatectomy.
However, a recent systematic review and meta-analysis
showed that neoadjuvant hormone therapy before prosta-
tectomy does not improve the overall survival and disease-
free survival, while it does improve the pathological out-
come [5].
Docetaxel remains the standard first-line chemotherapy
in castration resistant PCa based on two large randomized
trials demonstrating improved overall survival compared
to mitoxantrone [6,7]. However, in the setting of neoadju-
vant therapy, chemotherapy with docetaxel as a single
agent has minimal value in PCa patients treated with radi-
cal prostatectomy without pathological CR [8,9]. Recent
studies showed the benefit and clinicopathological results
of neoadjuvant chemohormonal therapy in patients with
high-risk localized PCa, including the combination chemo-
hormonal therapy with other cytotoxic drugs that includes
estramustine phosphate [10-13]. Although the true effect
remains controversial because of the large variations in the
schedule of neoadjuvant chemohormonal therapy and lack
of results from large randomized trials, a neoadjuvant che-
mohormonal therapy could have a role in the treatment of
patients with a high risk of PCa.
Here, we conducted a small pilot study to assess the
short-term outcome of neoadjuvant chemohormonal ther-
apy comprising complete androgen blockade followed by
treatment with docetaxel and estramustine phosphate
after radical prostatectomy in Japanese patients with high-
risk localized PCa.
Methods
Patient selection
Eligibility criteria included patients with histopathologi-
cally documented, locally advanced “high risk” of PCa
who were judged to be candidates for radical prostatect-
omy performed at Akita University Hospital, Akita,
Japan. “High-risk” disease was defined as any of the fol-
lowing requirements such as clinical stage T3, preopera-
tive PSA level of 15 ng/mL or greater, and/or Gleason
score greater than 9. The definition of the criteria for
high-risk prostate cancer was based on our previous
data of radical prostatectomies without neoadjuvant or
adjuvant hormonal therapy. In the previous data, a more
significant difference in the PSA recurrence-free survival
rate was observed when a Gleason score of 9 or 10 was
defined as high-risk criteria than when a score of 8-10
was included. Regarding the PSA level, we also found
that a more significant difference in the PSA recur-
rence-free survival rate was observed when the cut-off
value was 15 ng/mL than when the value was 20 ng/mL.
Staging was according to the TNM classification (UICC
1997). Clinical stage was assigned on the basis of digital
rectal examination findings, CT imaging, and bone scin-
tigraphy. Patients were excluded from participating in
the study if they received prior therapy for PCa, had
prior invasive malignancy, or any serious comorbidities.
Patients having ECOG performance status with 2 or
greater were excluded. All patients provided written
informed consent. The study was approved by the Insti-
tutional Review Boards (Ethical Committee) of Akita
University.
Treatment protocol
Treatment consisted of complete androgen blockade with
subcutaneous administration of 11.25 mg leuprorelin once
every 3 months and oral administration of 81 mg bicaluta-
mide for the first 12 weeks. Next, docetaxel was adminis-
tered intravenously at a dose of 30 mg/m
2 weekly for
6 consecutive weeks along with oral administration of
560 mg estramustine phosphate twice a day. Estramustine
phosphate was allowed to be decreased to 50% if patients
had dysphagia, nausea or vomiting. Patients were with-
drawn from the study if hematologic, hepatic or other
grade 3 or grade 4 non-hematologic toxicities did not
resolve within 3 weeks.
Patients then underwent modified extended radical
prostatectomy as reported by Miyake et al. [14], and a
bilateral pelvic lymphadenectomy according to a standar-
dized technique [15] under general anesthesia within 4
weeks after the last administration of docetaxel. One
patient who was suspected of having direct invasion into
the bladder underwent radical cystoprostatectomy after
neoadjuvant chemohormonal therapy.
Monitoring
After radical prostatectomy, patients were followed up
every 3 months and assessed for serum PSA levels. Bio-
chemical disease progression was defined as the serum
PSA level greater than 0.2 ng/mL.
Pathologic evaluation
Standard pathological examination of prostatectomy
specimens was performed at Akita University Hospital.
Narita et al. World Journal of Surgical Oncology 2012, 10:1
http://www.wjso.com/content/10/1/1
Page 2 of 6The pathological response to the neoadjuvant therapy
was assessed by a single pathologist (H.N.). Pathological
complete response was defined as complete eradication
of the tumor. According to the General rule for Clinical
and Pathological Studies on PCa recommended by the
Japanese Urological Association, Japanese Society of
Pathology, and the Japan Radiological Society [16],
pathological changes after chemohormonal therapy were
graded as follows: grade 0a (viable cells in all cancer
areas and no degenerated cells), grade 0b (viable cells in
all the specimen with degenerated cells), grade 1 (viable
cells in half or less of cancer areas), grade 2 (viable cells
in more than half of cancer areas), grade 3a (non-viable
cancer cells), and grade 3b (no cancer cells). No detect-
able viable cell (grade 3) in whole specimens was
defined as pathological complete response (CR).
Endopoints and Statistical analysis
The primary end point was the complete pathological CR.
Additional endpoints were safety, feasibility, and time to
biochemical failure. Toxicity was graded using Common
Toxicity Criteria (version 4.0). PSA progression-free survi-
val was defined as the time of surgery to the date of first
PSA recurrence and was calculated using the Kaplan-
Meier method.
Results
Patient characteristics
Eighteen patients were enrolled in this study from March
2006 to December 2010. The pretreatment characteristics
of the study population are listed in Table 1. The median
age was 67 years (range, 57-69 years), and the median pre-
treatment serum PSA level was 25.8 ng/mL (range, 5.1-
45.1 ng/mL). The ECOG performance status of all patients
was 0. The pretreatment Gleason score was 5 in 1 patient
(6.3%), 6 in 1 patient (6.3%),7 in 3 patients (18.8%), 8 in 1
patient (6.3%), 9 in 7 patients (43.8%), and 10 in 3 patients
(18.8). Nine patients (56.3%) had clinically organ-confined
disease, and 6 patients (37.5%) had cT3 disease. Six
patients (33.3%) had one of the 3 risk factors in our high-
risk criteria, 7 patients (38.9%) had 2 risk factors, and 5
patients (27.8%) had all 3 risk factors.
Adverse events
The prevalence of adverse events are summarized in
Table 2. Grade 3 or grade 4 hematological adverse events
were not observed. The elevation of serum transaminase
level with grade 3 was found in 1 patient, who recovered
within 4 weeks. In patient number 3 and 14, docetaxel
administration was abandoned after 5 courses. In patient
number 12, only 3 courses of docetaxel administration
was given because of mild nausea (Table 3). With respect
to postoperative complications, 1 patient with a ureteral
injury required cystoureterostomy 15 days after radical
prostatectomy. Another patient who had a lymphocele
required drainage for 25 days.
Surgical outcome
All patients underwent radical prostatectomy and bilat-
eral pelvic lymphadenectomy. The median serum PSA
level before surgery was 0.097 ng/mL (range, 0.002-
0.932). The tumor characteristics of surgical specimens
are listed in Table 3. The pathological changes in our
series were grade 0 in 1 patient (0.6%), grade 1 in 5
patients (27.8%), and grade 2 in 10 patients (55.6%).
Two patients (11.1%) had no detectable tumor (patholo-
gical CR). Surgical margins were negative in all patients.
Eleven patients (61.1%) had pathological T2 disease, and
2 patients (11.1%) had involvement of seminal vesicles
(T3b). The tumor disseminated into the pelvic lymph
nodes (pN1) in 4 patients (22.2%).
Table 1 Patient characteristics
No. patients %
Total no. of patients 18
Age, years
Median (range) 67 (57-69)
ECOG PS
0 18 100
Serum PSA, ng/mL
Median (range) 25.8 (5.1-45.1)
Clinical stage, T
1 3 18.8
2 6 37.5
3 6 37.5
4 1 6.3
Gleason score
5 1 6.3
6 1 6.3
7 3 18.8
8 1 6.3
9 7 43.8
10 3 18.8
Table 2 Adverse events
Grade
I II III IV
Hematological toxicity
Leukopenia 1 (6.3%) 0 0 0
Anemia 2 (11.1%) 1 (6.3%) 0 0
Thrombocytopenia 0 0 0 0
Non-hematological toxicity
Nausea/Vomiting 2 (11.1%) 2 (11.1%) 0 0
Diarrea 1 (6.3%) 0 0 0
Dysgeusia 1 (6.3%) 0 0 0
transamirase increased 0 1 (6.3%) 1 (6.3%) 0
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The median follow-up was 18 months (range, 1-49
months). All 4 patients with PSA recurrence (16.7%)
had pathological T3b or T4 disease, and 3 of these 4
patients had pathological lymph node positive disease.
The Kaplan-Meier curve shows that the PSA recur-
rence-free survival and median PSA recurrence-free sur-
vival was not attained (Figure 1).
Discussion
In this study, we elucidated the efficacy of the combina-
tion of neoadjuvant chemohormonal therapy comprising
complete androgen blockade followed by treatment with
docetaxel and estramustine phosphate after radical pros-
tatectomy in patients with high-risk of localized PCa.
This regimen had acceptable toxicity, negative surgical
margins, and two pathological CR.
T oo u rk n o w l e d g e ,o n l y2s t u d i e sh a v er e p o r t e dt h e
outcome of neoadjuvant chemohormonal therapy using
a combination of androgen deprivation followed by
treatment with docetaxel and estramustine phosphate
[12]. Sella et al. reported that combination therapy with
complete androgen blockage, 4 cycles of docetaxel (70
mg/m
2) on day 2, and estramustine phosphate (280 mg,
3t i m e sd a i l y )f r o md a y1t od a y5e v e r y2 1d a y si n2 2
poor prognosis localized PCa patients. They concluded
that there was no pathological CR with 63.6% of organ-
confined disease, 72.7% of specimen-confined disease,
40.9% of seminal vesicle invasion, and 18.1% of the
lymph node dissemination of tumors. At a median fol-
low-up of 23.6 months, 10 patients (45.5%) relapsed.
Prayer-Galetti et al. conducted a phase II study with
combination chemohormonal therapy with a longer fol-
low-up. Patients in their study received LHRH analog
until the PSA nadir, which was followed by a combined
regimen of estramustine phosphate (600 mg) and doce-
taxel (70 mg/m
2) for four 3-week cycles. Of 22 patients
enrolled in their study, 1 patient (5%) achieved patholo-
gical CR, and 6 patients (32%) had less than 10% resi-
dual tumor. At a median follow-up of 53 months, 14
patients (58%) relapsed with 23 months of median time
to recurrence. They also suggested that seminal vesicle
invasion and the volume of residual tumor were the
Table 3 Summary of patient outcomes
No. Age
(yrs)
BaselinePSA
(ng/ml)
Gleason
score
Clinical
stage
Preoperative PSA
(ng/ml)
Pathological
stage
Surgical
margin
Pathological
change
PSA progression
(mo)
1 58 17.0 7 T2aN0 0.083 T2bN0 negative 2 No
2 68 21.5 7 T1cN0 0.078 T2bN0 negative 2 No
3 69 15.0 9 T2aN0 0.045 T2aN0 negative 2 No
4 69 23.4 6 T3aN0 0.143 T2bN0 negative 2 No
5 67 42.9 9 T3aN0 0.133 T2bN0 negative 2 No
6 67 5.1 10 T1bN0 0.002 T0N0 negative 3b No
7 57 35.9 9 T3aN1 0.056 T3bN1 negative 1 6
8 64 28.3 9 T3aN0 0.084 T2bN0 negative 2 No
9 58 45.1 8 T3aN1 0.071 T3bN1 negative 2 No
10 66 37.8 7 T3bN0 0.11 T3bN1 negative 1 6
11 58 61.2 10 T4N0 0.52 T4N1 negative 1 7
12 62 30.7 5 T1cN0 0.498 T2aN0 negative 2 No
13 67 77.0 10 T2bN0 0.335 T3bN0 negative 1 6
14 67 21.4 9 T2bN0 0.132 T2bN0 negative 2 No
15 63 5.4 9 T2aN0 0.132 T2aN0 negative 1 No
16 68 17.3 9 T2cN0 0.036 T0N0 negative 3b No
17 71 25.3 7 T1cN0 0.017 T2aN0 negative 2 No
18 67 79.8 9 T1cN0 0.932 T2bN0 negative 0b No
Figure 1 PSA recurrence-free survival.
Narita et al. World Journal of Surgical Oncology 2012, 10:1
http://www.wjso.com/content/10/1/1
Page 4 of 6predictors of recurrence-free survival. It is difficult to
compare the results among this study including the pre-
sent study due to the variation in eligibility criteria,
quality of surgery, difference in the numbers of patients
evaluated, and duration of follow-up. However, recent
phase I/II studies of docetaxel with oral estramustine
have demonstrated comparable efficacy with less toxicity
in patients with castration-resistant PCa [17]. The com-
bination of docetaxel and estramustine phosphate is a
reliable option in the setting of neoadjuvant therapy.
Randomized studies are needed to clarify the role of
neoadjuvant chemohormonal therapy.
Within the follow-up period, the present study had 4
patients with PSA recurrence. In addition, all 4 patients
with PSA recurrence had local invasive disease (pT3b or
pT4). Prayer-Galetti et al. reported that seminal vesicle
invasion is an independent prognostic factor for patients
with high risk of PCa treated with chemohormonal ther-
apy [10]. Prediction of local invasion may therefore be
important for the selection of patients treated with
neoadjuvant chemohormonal therapy. Two patients had
small enlarged lymph nodes that were detected upon
abdominal CT scan before treatment, and thus they
were considered to be eligible for neoadjuvant therapy,
because of the possibility to have a non-cancerous enlar-
gement of lymph nodes. Considering the pathological
results retrospectively, it was found that the enlarged
lymph nodes were the lymph node metastases of PCa.
However, 1 of these patients had no PSA progression
for 18 months. It was also found that patients with
pathologically positive lymph nodes had a higher recur-
rence rate, and thus the prognosis of patients with
pathological lymph node dissemination is unclear.
Previous animal studies have shown that simultaneous
chemohormonal therapy is better than sequential chemo-
hormonal therapy in reducing disease progression [18].
Clinically, it remains controversial because the timing of
combination has differed in each study. However, recent
evidence suggests that castrated patients with PCa have a
high clearance of docetaxel and they have less adverse
effects [19]. In addition, patients in the present study had
no severe adverse effect during chemohormonal therapy
except the elevation of serum transaminase. Collectively,
sequential therapy may be more feasible to neoadjuvant
therapy in PCa patients treated with androgen deprivation
followed by chemotherapy.
Three patients had unsuccessful completion of the
administration of 6 sequential cycles of docetaxel. The
reasons for cancellation of the treatment were: (1) diffi-
culty in attending a hospital (2 patients) and (2) grade 2
nausea (1 patient). It would be necessary to validate
whether incomplete administration of docetaxel affects
the outcome in patients treated with our protocol.
The present study had certain limitations. Firstly,
assessing the contribution of each agent for the effect
and outcome in patients was difficult, because we could
not define if the effect was only due to chemotherapy or
due to a late effect of prolonging complete androgen
blockade. Secondly, testosterone was suppressed by the
administration of estramustine phosphate, which has a
long half-life. In the light of this fact, the effect of estra-
mustine phosphate should be considered to assess PSA
recurrence after surgery. The serum testosterone levels
need to be continuously assessed after surgery. Finally,
the duration of follow-up was only 18 months, which
was shorter than that in previous reports. Prayer-Galleti
et al. showed that the median time to PSA recurrence in
patients treated with combination therapy was 23
months [10]. Further validation is required to assess the
long-term outcome and suitable patients for neoadju-
vant chemohormonal therapy with a high risk of loca-
lized PCa.
Conclusions
We found that neoadjuvant chemohormonal therapy
with complete androgen blockade followed by treatment
with docetaxel and estramustine phosphate before radi-
cal prostatectomy was safe, feasible, and associated with
favorable pathological outcomes in patients with a high
risk of localized PCa. Although ongoing randomized
phase II trials such as CALGB 90203 and GETUG12
may help to assess the efficacy of neoadjuvant chemo-
hormonal therapy, our regimen may be a candidate for
the optimal chemohormonal therapy in patients with
high-risk localized PCa.
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